Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $1.1 million.

  • Pharma's Cash & Equivalents fell 2690.82% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 2690.82%. This contributed to the annual value of $405000.0 for FY2025, which is 6625.0% down from last year.
  • Latest data reveals that Pharma reported Cash & Equivalents of $1.1 million as of Q3 2025, which was down 2690.82% from $454000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Cash & Equivalents registered a high of $14.5 million during Q1 2021, and its lowest value of $405000.0 during Q1 2025.
  • Over the past 5 years, Pharma's median Cash & Equivalents value was $3.1 million (recorded in 2023), while the average stood at $5.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 115099.91% in 2021, then plummeted by 7578.54% in 2023.
  • Over the past 5 years, Pharma's Cash & Equivalents (Quarter) stood at $11.9 million in 2021, then tumbled by 57.85% to $5.0 million in 2022, then plummeted by 72.62% to $1.4 million in 2023, then plummeted by 65.89% to $470000.0 in 2024, then surged by 140.43% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $454000.0 for Q2 2025, and $405000.0 during Q1 2025.